The Netherlands' national pediatric cancer center combining clinical care with frontier molecular research on childhood tumor biology, organoid-based drug testing, and survivorship.
Princess Máxima Center is the Netherlands' national center for pediatric oncology, consolidating all childhood cancer treatment and research under one roof in Utrecht. They combine clinical care with deep molecular research — from understanding tumor origins and evolution at the single-cell level to developing precision drug combinations tested on patient-derived organoids. Their H2020 work spans preclinical drug development, cancer survivorship care for childhood cancer survivors, and building European data infrastructure for pediatric oncology. They are both a treatment hospital and a research powerhouse focused exclusively on children's cancer.
Core focus across RhabdoEvo (rhabdoid tumor origins), CANCER INVASION (diffuse intrinsic pontine glioma), SecondCANCERinKIDS (therapy-related malignancies), DynaMech (transcription factor dynamics), PREDICT, and ITCC-P4.
PREDICT focuses on neuroblastoma organoids for precision medicine, ITCC-P4 builds a pediatric preclinical platform with PDX/GEMM/organoid models, VAGABOND validates target-drug combinations, and HCA Organoid establishes multi-tissue organoid reference maps.
PanCareFollowUp develops person-centred survivorship guidelines, PanCareSurPass implements digital Survivorship Passports, and HARMONIC studies health effects of radiation in pediatric patients.
AiPBAND develops brain cancer diagnostic biosensing techniques, diaRNAgnosis profiles circulating cell-free RNA as liquid biopsy biomarkers, and ITCC-P4 includes biomarker-driven relapse detection.
iPC builds cloud-based virtual patient models with HPC for precision pediatric oncology, and AiPBAND applies machine learning to cancer diagnostics.
In their early H2020 period (2016–2018), the center focused on foundational cancer biology — transcription factor dynamics, building preclinical testing platforms (PDX, GEMM, organoids), and brain cancer diagnostics with biosensing techniques. From 2019 onward, their work shifted decisively toward understanding tumor evolution at the single-cell and epigenomic level (RhabdoEvo, SecondCANCERinKIDS), radiation health effects in children, and translating research into clinical survivorship care. There is a clear maturation arc: from building laboratory platforms to applying them for precision medicine and long-term patient outcomes.
Moving toward integrating single-cell genomics with clinical decision-making and building European-scale survivorship infrastructure — future partners should expect projects combining deep molecular data with real patient outcomes.
With 7 coordinated and 9 participant roles across 16 projects, Princess Máxima is a confident consortium leader that also contributes as a specialist partner in larger networks. Their 146 unique partners across 25 countries show they operate as a European hub for pediatric oncology research, not a closed institution. They lead their own ERC-funded fundamental research while joining large multi-partner clinical and translational consortia — making them both an independent research force and a cooperative network builder.
Extensive European network of 146 unique partners spanning 25 countries, reflecting their role as a central node in pediatric oncology research. Their partnerships range from clinical hospital networks (ChiLTERN, PanCare) to computational research groups (iPC) and capacity-building in widening countries (TREL with Lithuania).
Princess Máxima is one of very few institutions in Europe that combines being a dedicated national pediatric cancer hospital with running frontier molecular research — most children's hospitals don't coordinate ERC grants, and most ERC labs don't treat patients. Their organoid-based precision medicine pipeline connects lab discoveries directly to clinical trials for childhood cancers, which are rare diseases with limited commercial drug development. For any consortium targeting pediatric oncology, rare childhood tumors, or cancer survivorship, they are arguably the strongest single partner in Europe.
